This phenomenon may be partially explained by the assumption that older patients may have less aggressive variants of underlying tumor biology [14] and, thus, are more likely to respond to PSMA-targeted RLT, irrespective of the agent. This evidence concerns the gene FOLH1 and neoplasm.